Hans Herfarth, MD
Gastroenterology · Chapel Hill, NCNPI 1538246574
Payments from drug & device makers
Across 351 payments — averaging $5680.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$943K
- AbbVie$408K
- Novo Nordisk$153K
- Roche Products Limited$133K
- Janssen Research & Development, LLC$131K
- Takeda Pharmaceuticals U.S.A., Inc.$71K
- plus $153K from 12 others
Across 7 payments — averaging $46,758 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$318K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$4K
- Teva Pharmaceuticals USA, Inc.$4K
- Pfizer$2K
What the payments were for
- Consulting fees$68,52388%
- Speaking & faculty fees$6,0008%
- Travel & lodging$2,1903%
- Food & beverage$7451%
- Education$1510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 15 | $943,282 |
| AbbVie | 114 | $408,061 |
| Novo Nordisk | 10 | $153,458 |
| Roche Products Limited | 46 | $133,444 |
| Janssen Research & Development, LLC | 29 | $131,481 |
| Takeda Pharmaceuticals U.S.A., Inc. | 42 | $70,987 |
| Genentech, Inc. | 20 | $35,240 |
| Gilead | 19 | $32,550 |
| E.r. Squibb & Sons, L.L.C. | 3 | $28,229 |
| Johnson & Johnson | 22 | $26,012 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $8,201 |
| Eli Lilly | 21 | $8,070 |
| Celltrion USA Inc. | 3 | $4,531 |
| Redhill Biopharma Inc. | 2 | $4,230 |
| Boehringer Ingelheim | 1 | $2,880 |
| Bausch Health US, LLC | 1 | $2,325 |
| Fresenius Kabi USA, LLC | 1 | $610 |
| Biogen | 1 | $150 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,993,743 in reported general payments places this provider in the 95th percentile of 610 gastroenterology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GattexTeduglutide | 73 | $3,792,403 |
| StelaraUstekinumab | 121 | $3,272,387 |
| Humira(Cf) PenAdalimumab | 87 | $929,655 |
| Skyrizi On-BodyRisankizumab-Rzaa | 30 | $602,034 |
| Humira(Cf)Adalimumab | 22 | $304,340 |
| RenflexisInfliximab-Abda | 13 | $38,576 |
| LinzessLinaclotide | 15 | $10,742 |
| Mesalamine | 13 | $10,627 |
| Opium Tincture | 22 | $8,389 |
| Octreotide Acetate | 13 | $6,242 |
| LoperamideLoperamide Hcl | 64 | $5,138 |
| Cefdinir | 69 | $5,092 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 62 | $4,894 |
| Budesonide DrBudesonide | 13 | $3,583 |
| Balsalazide Disodium | 11 | $3,342 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gattex | $70,987 | $3,792,40373 claims |
| Johnson & JohnsonStelara | $26,012 | $3,272,387121 claims |
| AbbVieHumira(Cf), Linzess | $408,061 | $315,08237 claims |
| Fresenius Kabi USA, LLCMagnesium Sulfate, Sodium Chloride, Sodium Chloride | $610 | $1,14180 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 610 gastroenterology providers in North Carolina.
Other gastroenterology in Chapel Hill
- Evan DellonChapel Hill$11.2M
- Nicholas ShaheenChapel Hill$1.5M
- Alfred BarrittChapel Hill$1.3M
- Paul WatkinsChapel Hill$1.1M
- Kim IsaacsChapel Hill$725K
- Ryan SartorChapel Hill$671K
- Shehzad SheikhChapel Hill$324K
- Christine HuntChapel Hill$122K
- Andrew MuirDurham$6.6M
- Manal AbdelmalekDurham$5.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.